S&P 500   3,465.39 (+0.34%)
DOW   28,335.57 (-0.10%)
QQQ   284.74 (+0.20%)
AAPL   115.04 (-0.61%)
MSFT   216.23 (+0.62%)
FB   284.79 (+2.40%)
GOOGL   1,632.98 (+1.64%)
AMZN   3,204.40 (+0.88%)
TSLA   420.63 (-1.21%)
NVDA   543.61 (+1.72%)
BABA   309.92 (+1.19%)
CGC   19.73 (-2.81%)
GE   7.63 (-1.17%)
MU   52.85 (-2.81%)
AMD   81.96 (+3.20%)
T   27.82 (-1.63%)
F   8.16 (-0.61%)
ACB   4.68 (-3.51%)
GILD   60.79 (+0.20%)
NFLX   488.28 (+0.63%)
BA   167.36 (-1.01%)
NIO   27.16 (-0.80%)
DIS   128.35 (+0.62%)
S&P 500   3,465.39 (+0.34%)
DOW   28,335.57 (-0.10%)
QQQ   284.74 (+0.20%)
AAPL   115.04 (-0.61%)
MSFT   216.23 (+0.62%)
FB   284.79 (+2.40%)
GOOGL   1,632.98 (+1.64%)
AMZN   3,204.40 (+0.88%)
TSLA   420.63 (-1.21%)
NVDA   543.61 (+1.72%)
BABA   309.92 (+1.19%)
CGC   19.73 (-2.81%)
GE   7.63 (-1.17%)
MU   52.85 (-2.81%)
AMD   81.96 (+3.20%)
T   27.82 (-1.63%)
F   8.16 (-0.61%)
ACB   4.68 (-3.51%)
GILD   60.79 (+0.20%)
NFLX   488.28 (+0.63%)
BA   167.36 (-1.01%)
NIO   27.16 (-0.80%)
DIS   128.35 (+0.62%)
S&P 500   3,465.39 (+0.34%)
DOW   28,335.57 (-0.10%)
QQQ   284.74 (+0.20%)
AAPL   115.04 (-0.61%)
MSFT   216.23 (+0.62%)
FB   284.79 (+2.40%)
GOOGL   1,632.98 (+1.64%)
AMZN   3,204.40 (+0.88%)
TSLA   420.63 (-1.21%)
NVDA   543.61 (+1.72%)
BABA   309.92 (+1.19%)
CGC   19.73 (-2.81%)
GE   7.63 (-1.17%)
MU   52.85 (-2.81%)
AMD   81.96 (+3.20%)
T   27.82 (-1.63%)
F   8.16 (-0.61%)
ACB   4.68 (-3.51%)
GILD   60.79 (+0.20%)
NFLX   488.28 (+0.63%)
BA   167.36 (-1.01%)
NIO   27.16 (-0.80%)
DIS   128.35 (+0.62%)
S&P 500   3,465.39 (+0.34%)
DOW   28,335.57 (-0.10%)
QQQ   284.74 (+0.20%)
AAPL   115.04 (-0.61%)
MSFT   216.23 (+0.62%)
FB   284.79 (+2.40%)
GOOGL   1,632.98 (+1.64%)
AMZN   3,204.40 (+0.88%)
TSLA   420.63 (-1.21%)
NVDA   543.61 (+1.72%)
BABA   309.92 (+1.19%)
CGC   19.73 (-2.81%)
GE   7.63 (-1.17%)
MU   52.85 (-2.81%)
AMD   81.96 (+3.20%)
T   27.82 (-1.63%)
F   8.16 (-0.61%)
ACB   4.68 (-3.51%)
GILD   60.79 (+0.20%)
NFLX   488.28 (+0.63%)
BA   167.36 (-1.01%)
NIO   27.16 (-0.80%)
DIS   128.35 (+0.62%)
Log in
NASDAQ:BCLI

Brainstorm Cell Therapeutics SEC Filings & 10K Form

$10.75
+0.56 (+5.50 %)
(As of 10/23/2020 05:08 PM ET)
Add
Compare
Today's Range
$10.20
Now: $10.75
$10.90
50-Day Range
$9.51
MA: $14.64
$17.73
52-Week Range
$3.58
Now: $10.75
$17.95
Volume722,354 shs
Average Volume652,563 shs
Market Capitalization$339.36 million
P/E RatioN/A
Dividend YieldN/A
Beta0.83

SEC Filings

Brainstorm Cell Therapeutics (NASDAQ:BCLI) SEC Filings

DateFilerForm TypeView
10/15/2020
6:15 AM
Brainstorm Cell Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/15/2020
6:00 AM
Brainstorm Cell Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
09/25/2020
3:16 PM
Brainstorm Cell Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/25/2020
3:14 PM
Brainstorm Cell Therapeutics (Filer)
Form 424B5
09/10/2020
3:07 PM
Brainstorm Cell Therapeutics (Issuer)
Waclawski Anthony (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/10/2020
3:05 PM
Brainstorm Cell Therapeutics (Issuer)
Waclawski Anthony (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
08/05/2020
6:00 AM
Brainstorm Cell Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/16/2020
4:15 PM
Abbhi Sankesh (Reporting)
Brainstorm Cell Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/26/2020
4:02 PM
Brainstorm Cell Therapeutics (Filer)
Form 424B3
06/26/2020
4:01 PM
Brainstorm Cell Therapeutics (Filer)
Form 424B3
06/01/2020
4:32 PM
Brainstorm Cell Therapeutics (Issuer)
Lindborg Stacy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/01/2020
4:31 PM
Brainstorm Cell Therapeutics (Issuer)
Lindborg Stacy (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
05/08/2020
11:04 AM
Brainstorm Cell Therapeutics (Subject)
Daly Joseph Patrick (Filed by)
Form SC 13D/A
05/07/2020
5:31 AM
Brainstorm Cell Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/08/2020
5:01 AM
Abbhi Investments, LLC (Filed by)
Brainstorm Cell Therapeutics (Subject)
Form SC 13D
04/07/2020
5:16 PM
Brainstorm Cell Therapeutics (Issuer)
Setboun David (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/07/2020
5:15 PM
Brainstorm Cell Therapeutics (Issuer)
Setboun David (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
04/07/2020
5:14 PM
Brainstorm Cell Therapeutics (Issuer)
FRENKEL JACOB A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/07/2020
5:13 PM
Brainstorm Cell Therapeutics (Issuer)
FRENKEL JACOB A (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
04/07/2020
5:12 PM
Abbhi Sankesh (Reporting)
Brainstorm Cell Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/07/2020
5:11 PM
Abbhi Sankesh (Reporting)
Brainstorm Cell Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
03/31/2020
6:51 AM
Brainstorm Cell Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/17/2020
8:30 PM
Abbhi Investments, LLC (Filed by)
Brainstorm Cell Therapeutics (Subject)
Form SC 13G
03/06/2020
4:06 PM
Brainstorm Cell Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/06/2020
4:04 PM
Brainstorm Cell Therapeutics (Filer)
Form 424B5
03/06/2020
1:35 PM
Brainstorm Cell Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/06/2020
1:32 PM
Brainstorm Cell Therapeutics (Filer)
Form 424B5
02/18/2020
6:01 AM
Brainstorm Cell Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/14/2020
4:00 PM
Brainstorm Cell Therapeutics (Issuer)
Polverino Anthony J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/14/2020
4:00 PM
Almenoff June Sherie (Reporting)
Brainstorm Cell Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/27/2019
6:01 AM
Brainstorm Cell Therapeutics (Issuer)
Kern Ralph Dr. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/27/2019
6:01 AM
Brainstorm Cell Therapeutics (Issuer)
Shah Preetam (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/27/2019
6:00 AM
Araya Arturo (Reporting)
Brainstorm Cell Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2019
4:00 PM
Brainstorm Cell Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/21/2019
6:15 AM
Brainstorm Cell Therapeutics (Subject)
Daly Joseph Patrick (Filed by)
Form SC 13D
11/14/2019
5:01 AM
Brainstorm Cell Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
09/09/2019
7:01 AM
Brainstorm Cell Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/09/2019
7:00 AM
Brainstorm Cell Therapeutics (Issuer)
Shah Preetam (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/09/2019
7:00 AM
Brainstorm Cell Therapeutics (Issuer)
Shah Preetam (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
09/02/2019
11:15 PM
Brainstorm Cell Therapeutics (Filer)
Form EFFECT
08/30/2019
4:02 PM
ARBEL IRIT (Reporting)
Brainstorm Cell Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/30/2019
4:01 PM
Brainstorm Cell Therapeutics (Filer)
Form 424B1
08/16/2019
4:17 PM
Brainstorm Cell Therapeutics (Filer)
Form S-3
Registration statement under Securities Act of 1933  
08/13/2019
5:03 AM
Brainstorm Cell Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/09/2019
4:09 PM
Brainstorm Cell Therapeutics (Filer)
Form D
Notice of Exempt Offering of Securities 
08/02/2019
4:01 PM
Brainstorm Cell Therapeutics (Filer)
Form 424B3
08/02/2019
8:30 AM
Brainstorm Cell Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/26/2019
4:03 PM
Brainstorm Cell Therapeutics (Issuer)
Lebovits Chaim (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/26/2019
4:03 PM
Brainstorm Cell Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/11/2019
4:01 PM
Brainstorm Cell Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/11/2019
4:01 PM
Brainstorm Cell Therapeutics (Filer)
Form 424B5
05/13/2019
7:00 AM
Brainstorm Cell Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/10/2019
4:01 PM
Brainstorm Cell Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/01/2019
2:34 PM
Brainstorm Cell Therapeutics (Filer)
Form 10-K/A
03/12/2019
5:12 AM
Brainstorm Cell Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/08/2019
4:02 PM
Brainstorm Cell Therapeutics (Issuer)
Kern Ralph Dr. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2019
8:00 AM
Almenoff June Sherie (Reporting)
Brainstorm Cell Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/21/2018
3:33 PM
Brainstorm Cell Therapeutics (Issuer)
Schor Chen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/21/2018
3:32 PM
Brainstorm Cell Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
11/30/2018
4:05 PM
Brainstorm Cell Therapeutics (Issuer)
Schor Chen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/30/2018
4:05 PM
Brainstorm Cell Therapeutics (Issuer)
Polverino Anthony J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/30/2018
4:04 PM
ARBEL IRIT (Reporting)
Brainstorm Cell Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/30/2018
4:03 PM
Brainstorm Cell Therapeutics (Issuer)
Yablonka Uri (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/30/2018
4:01 PM
Brainstorm Cell Therapeutics (Issuer)
TAUB MALCOLM S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/30/2018
4:00 PM
Brainstorm Cell Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/29/2018
5:06 AM
Brainstorm Cell Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/10/2018
7:00 AM
Brainstorm Cell Therapeutics (Filer)
Form DEF 14A
09/28/2018
4:26 PM
Brainstorm Cell Therapeutics (Filer)
Form 424B1
09/21/2018
4:17 PM
Brainstorm Cell Therapeutics (Filer)
Form S-3/A
09/04/2018
4:02 PM
Araya Arturo (Reporting)
Brainstorm Cell Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/27/2018
3:05 PM
Brainstorm Cell Therapeutics (Issuer)
Lebovits Chaim (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/23/2018
7:01 AM
Brainstorm Cell Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/01/2018
11:15 PM
Brainstorm Cell Therapeutics (Filer)
Form EFFECT
06/29/2018
3:07 PM
Brainstorm Cell Therapeutics (Filer)
Form S-3
Registration statement under Securities Act of 1933  
06/20/2018
5:03 AM
Brainstorm Cell Therapeutics (Filer)
Form D
Notice of Exempt Offering of Securities 
06/08/2018
10:40 AM
Brainstorm Cell Therapeutics (Filer)
Form S-3
Registration statement under Securities Act of 1933  
06/07/2018
7:06 AM
Brainstorm Cell Therapeutics (Filer)
Form 424B3
06/07/2018
7:00 AM
Brainstorm Cell Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/14/2018
7:01 AM
Brainstorm Cell Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
03/26/2018
3:49 PM
Brainstorm Cell Therapeutics (Issuer)
Kern Ralph Dr. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/26/2018
3:45 PM
Araya Arturo (Reporting)
Brainstorm Cell Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/20/2018
9:50 AM
Almenoff June Sherie (Reporting)
Brainstorm Cell Therapeutics (Issuer)
Form 4/A
03/20/2018
9:48 AM
Brainstorm Cell Therapeutics (Issuer)
Kern Ralph Dr. (Reporting)
Form 4/A
03/16/2018
5:06 AM
Almenoff June Sherie (Reporting)
Brainstorm Cell Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/08/2018
5:07 AM
Brainstorm Cell Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/05/2018
3:50 PM
Brainstorm Cell Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/05/2018
3:30 PM
Brainstorm Cell Therapeutics (Issuer)
Polverino Anthony J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2018
3:30 PM
Brainstorm Cell Therapeutics (Issuer)
Polverino Anthony J. (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
01/04/2018
7:30 AM
Brainstorm Cell Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
This page was last updated on 10/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.